These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 8581380

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.
    Glennie MJ, Brennand DM, Bryden F, McBride HM, Stirpe F, Worth AT, Stevenson GT.
    J Immunol; 1988 Nov 15; 141(10):3662-70. PubMed ID: 3141503
    [Abstract] [Full Text] [Related]

  • 8. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
    Tazzari PL, Bolognesi A, de Totero D, Falini B, Lemoli RM, Soria MR, Pileri S, Gobbi M, Stein H, Flenghi L.
    Br J Haematol; 1992 Jun 15; 81(2):203-11. PubMed ID: 1322690
    [Abstract] [Full Text] [Related]

  • 9. Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.
    Bonardi MA, French RR, Amlot P, Gromo G, Modena D, Glennie MJ.
    Cancer Res; 1993 Jul 01; 53(13):3015-21. PubMed ID: 7686448
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Different sensitivity of CD30+ cell lines to Ber-H2/saporin-S6 immunotoxin.
    Battelli MG, Bolognesi A, Olivieri F, Polito L, Stirpe F.
    J Drug Target; 1998 Jul 01; 5(3):181-91. PubMed ID: 9606008
    [Abstract] [Full Text] [Related]

  • 13. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE, Brown AN, Bremner JA, Foxwell BM, Stirpe F.
    J Natl Cancer Inst; 1985 Jul 01; 75(1):151-9. PubMed ID: 3859688
    [Abstract] [Full Text] [Related]

  • 14. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
    Falini B, Bolognesi A, Flenghi L, Tazzari PL, Broe MK, Stein H, Dürkop H, Aversa F, Corneli P, Pizzolo G.
    Lancet; 1992 May 16; 339(8803):1195-6. PubMed ID: 1349939
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.
    Tazzari PL, de Totero D, Bolognesi A, Testoni N, Pileri S, Roncella S, Reato G, Stein H, Gobbi M, Stirpe F.
    Haematologica; 1999 Nov 16; 84(11):988-95. PubMed ID: 10553158
    [Abstract] [Full Text] [Related]

  • 20. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ, Warnes SL, Noss AL, Flavell SU.
    Br J Cancer; 2000 Dec 16; 83(12):1755-61. PubMed ID: 11104577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.